New Trends in Pharmacological Treatments for Osteoarthritis

被引:71
作者
Cai, Xiaoyan [1 ]
Yuan, Shiwen [1 ]
Zeng, Yanting [1 ]
Wang, Cuicui [1 ]
Yu, Na [1 ]
Ding, Changhai [1 ,2 ,3 ]
机构
[1] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Rheumatol, Guangzhou, Peoples R China
[2] Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Guangzhou, Peoples R China
[3] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia
关键词
osteoarthritis; novel therapeutics; DMOADs; therapy selection; clinical prospect; POST-HOC ANALYSIS; SYMPTOMATIC KNEE OSTEOARTHRITIS; VITAMIN-D SUPPLEMENTATION; NERVE GROWTH-FACTOR; VARIABLE DOMAIN IMMUNOGLOBULIN; REDUCES CARTILAGE LOSS; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; STRONTIUM RANELATE; INTRAARTICULAR SPRIFERMIN;
D O I
10.3389/fphar.2021.645842
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoarthritis (OA) is the leading cause of function loss and disability among the elderly, with significant burden on the individual and society. It is a severe disease for its high disability rates, morbidity, costs, and increased mortality. Multifactorial etiologies contribute to the occurrence and development of OA. The heterogeneous condition poses a challenge for the development of effective treatment for OA; however, emerging treatments are promising to bring benefits for OA management in the future. This narrative review will discuss recent developments of agents for the treatment of OA, including potential disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics for pain relief. This review will focus more on drugs that have been in clinical trials, as well as attractive drugs with potential applications in preclinical research. In the past few years, it has been realized that a complex interaction of multifactorial mechanisms is involved in the pathophysiology of OA. The authors believe there is no miracle therapeutic strategy fitting for all patients. OA phenotyping would be helpful for therapy selection. A variety of potential therapeutics targeting inflammation mechanisms, cellular senescence, cartilage metabolism, subchondral bone remodeling, and the peripheral nociceptive pathways are expected to reshape the landscape of OA treatment over the next few years. Precise randomized controlled trials (RCTs) are expected to identify the safety and efficacy of novel therapies targeting specific mechanisms in OA patients with specific phenotypes.
引用
收藏
页数:16
相关论文
共 149 条
[1]   RETRACTED: Retracted: Methotrexate in the treatment of symptomatic knee osteoarthritis: randomised placebo-controlled trial (Retracted Article) [J].
Abou-Raya, A. ;
Abou-Raya, S. ;
Khadrawe, T. .
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (07)
[2]   A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial [J].
Aitken, D. ;
Laslett, L. L. ;
Pan, F. ;
Haugen, I. K. ;
Otahal, P. ;
Bellamy, N. ;
Bird, P. ;
Jones, G. .
OSTEOARTHRITIS AND CARTILAGE, 2018, 26 (07) :880-887
[3]   Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines [J].
Arden, Nigel K. ;
Perry, Thomas A. ;
Bannuru, Raveendhara R. ;
Bruyere, Olivier ;
Cooper, Cyrus ;
Haugen, Ida K. ;
Hochberg, Marc C. ;
McAlindon, Timothy E. ;
Mobasheri, Ali ;
Reginster, Jean-Yves .
NATURE REVIEWS RHEUMATOLOGY, 2021, 17 (01) :59-66
[4]   Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation [J].
Bakker, AC ;
van de Loo, FAJ ;
van Beuningen, HM ;
Sime, P ;
van Lent, PLEM ;
van der Kraan, PM ;
Richards, CD ;
van den Berg, WB .
OSTEOARTHRITIS AND CARTILAGE, 2001, 9 (02) :128-136
[5]   Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data [J].
Bally, Michele ;
Dendukuri, Nandini ;
Rich, Benjamin ;
Nadeau, Lyne ;
Helin-Salmivaara, Arja ;
Garbe, Edeltraut ;
Brophy, James M. .
BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
[6]   Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period [J].
Berenbaum, Francis ;
Blanco, Francisco J. ;
Guermazi, Ali ;
Miki, Kenji ;
Yamabe, Takaharu ;
Viktrup, Lars ;
Junor, Rod ;
Carey, William ;
Brown, Mark T. ;
West, Christine R. ;
Verburg, Kenneth M. .
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (06) :800-810
[7]   Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study [J].
Brett, A. ;
Bowes, M. A. ;
Conaghan, P. G. ;
Ladel, C. ;
Guehring, H. ;
Moreau, F. ;
Eckstein, F. .
OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (11) :1432-1436
[8]   Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions A Randomized Clinical Trial [J].
Cai, Guoqi ;
Aitken, Dawn ;
Laslett, Laura L. ;
Pelletier, Jean-Pierre ;
Martel-Pelletier, Johanne ;
Hill, Catherine ;
March, Lyn ;
Wluka, Anita E. ;
Wang, Yuanyuan ;
Antony, Benny ;
Blizzard, Leigh ;
Winzenberg, Tania ;
Cicuttini, Flavia ;
Jones, Graeme .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (15) :1456-1466
[9]   Pharmacotherapy for knee osteoarthritis: current and emerging therapies [J].
Cao, Peihua ;
Li, Yamin ;
Tang, Yujin ;
Ding, Changhai ;
Hunter, David J. .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (07) :797-809
[10]   A high-throughput quantification method of curcuminoids and curcumin metabolites in human plasma via high-performance liquid chromatography/tandem mass spectrometry [J].
Cao, Yu ;
Xu, Ronald X. ;
Liu, Zhongfa .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2014, 949 :70-78